All Insights White Paper The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

    The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

    Sales Operations

    The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

    This paper talks about suggested actions biopharmaceutical companies should take in response to increasing access restrictions of sales reps to physicians.

    Download White Paper
    The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

    The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to physicians in all settings.  With very few exceptions, the prevailing narrative has gone unchallenged.  This paper provides a more in-depth and balanced look into the evidence supporting the current narrative and presents suggested actions biopharmaceutical companies should take in response to increasing access restrictions of sales reps to physicians.

    Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

    Contact us at insights@axtria.com for any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Evidence Supporting Sales Rep Access Restrictions to Physicians

    Blog

    Virtual Versus In-person Calls: Are Sales Reps Better Off In The Digital World?

    Evidence Supporting Sales Rep Access Restrictions to Physicians

    White Paper

    Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?

    Evidence Supporting Sales Rep Access Restrictions to Physicians

    White Paper

    The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”